224 related articles for article (PubMed ID: 2760634)
1. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
[TBL] [Abstract][Full Text] [Related]
2. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
6. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Poewe WH; Lees AJ; Stern GM
Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
[TBL] [Abstract][Full Text] [Related]
8. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Ohmoto T; Kishikawa H
Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
[TBL] [Abstract][Full Text] [Related]
11. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
Dietrichson P; Presthus J; Holmsen R
Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
Dowzenko A; Buksowicz C; Kuran W
Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
[TBL] [Abstract][Full Text] [Related]
14. Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Feuerstein C; Tanche M; Serre F; Gavend M; Pellat J; Perret J
Acta Neurol Scand; 1977 Jul; 56(1):79-82. PubMed ID: 878846
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
[TBL] [Abstract][Full Text] [Related]
16. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
[TBL] [Abstract][Full Text] [Related]
17. Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Boomsma F; Ausema L; Hakvoort-Cammel FG; Oosterom R; Man in't Veld AJ; Krenning EP; Hahlen K; Schalekamp MA
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1045-52. PubMed ID: 2503383
[TBL] [Abstract][Full Text] [Related]
18. Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Weller C; O'Neill CJ; Charlett A; Bowes SG; Purkiss A; Nicholson PW; Dobbs RJ; Dobbs SM
Br J Clin Pharmacol; 1993 Apr; 35(4):379-85. PubMed ID: 8485018
[TBL] [Abstract][Full Text] [Related]
19. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
